HD-OPM Archive
Topics › Plaque, CAC & CT angiography

Keto-CTA plaque progression vs plaque regression on Repatha in Budoff's other study

Louis Nervegna · Apr 09, 2025 · ♥ 8 reactions · 2 comments · original Facebook post
Plaque, CAC & CT angiographyPCSK9, ezetimibe & newer drugsLow-carb, keto & carnivore
AI summary & key facts

Louis compares non-calcified plaque volume (NCPV) changes in the Keto-CTA (LMHR) study with a second Matthew Budoff study in higher-risk people whose LDL was lowered to about 30 mg/dL with the PCSK9 inhibitor Repatha. The lean, healthy keto group with LDL 254 mg/dL progressed, while the hypertensive, higher-risk Repatha group mostly showed major regression. He also notes that uL and mm^3 are the same unit when comparing NCPV across studies.

Let's look at the changes in non-calcified plaque volume (NCPV) in the recent Keto-CTA (LMHR) trial.

In the first image, we see the changes in NCPV in the keto trial among people with an average LDL of 254 mg/dL. Overall, we see significant increases. The higher the baseline plaque volume level, the greater the increase in non-calcified plaque volume. All participants saw plaque progression or neutral.

For comparison, we have a recent study by the same principal investigator Matthew Budoff. In the second image we see changes in the same parameter (non-calcified plaque volume) in people with additional risk factors for atherosclerosis such as hypertension (53%) and diabetes (21%) and with a high baseline level of non-calcified plaque volume.

These people had their LDL levels intensively lowered with the PCSK9 inhibitor Repatha to around 30 mg/dl. Most participants saw major plaque regression.

In this comparison, the keto trial results look bad.

The lean metabolically-healthy group on keto with very high LDL shows significant plaque progression, despite having low plaque volume to begin with.

The hypertensive overweight metabolically-unhealthy group with very low LDL shows significant plaque regression, despite having high plaque volume to begin with.

Access link to Matthew Budoff second study:

PaperScienceDirect articlesciencedirect.com

↪ Repatha for 18 months reduced non-calcified plaque on CT angiography in a 47-patient study

(This post is from the LMHR group on Facebook. I edited it to provide context.)

Reference for LMHR study:

Paper · JACC: Advances · 2025RETRACTED: Longitudinal Data From the KETO-CTA Studyjacc.org

Note that NCPV can be measured in either units of uL or units of mm^3. These are the same thing. One cubic millimeter (1 mm^3) is exactly the same volume as one microliter (1 uL). Keep this in mind when comparing different studies to one another.

#ketoctaHD #lmhrHD #ncpvHD #budoffHD #ketoctasummaryHD #reverseHD #pcsk9reverseHD #repathaHD

Research cited

← newer: Keto-CTA (LMHR): plaque volume rose 25-100% in one year acroolder: Keto-CTA: LMHR group's 0.8% plaque volume rise exceeded that →